What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.

Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.

Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice.

Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.

Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.

Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.

"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.

"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.

"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.

"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.